About Adnexus

Board of Directors

Adnexus' Board of Directors is composed of highly-experienced professionals from the biopharmaceutical industry, venture capital community, and academia.

L. Patrick Gage, Ph.D., Chairman, Adnexus Therapeutics, and Venture Partner, Flagship Ventures

L. Patrick Gage has served as a member of our board of directors since December 2002 and has served as Chairman of our board of directors since 2006. Since 2003, Dr. Gage has been a Venture Partner of Flagship Ventures. Between 1997 and 2002, Dr. Gage held various positions at Wyeth Pharmaceuticals, serving most recently as Senior Vice President, Science and Technology, and President, Wyeth Research. Prior to joining Wyeth, Dr. Gage held various positions at Genetics Institute most recently as its president. Prior to joining Genetics Institute, Dr. Gage held various positions in research management at F. Hoffmann-La Roche Ltd. over an 18-year period. Dr. Gage serves as Chairman of the board of directors of Neose Technologies, Inc. and PDL BioPharma, Inc., both publicly-traded companies, and is a member of the board of directors for several private companies. Dr. Gage received a B.S. in Physics from the Massachusetts Institute of Technology and a Ph.D. in Biophysics from the University of Chicago.

back to top

John Mendlein, Ph.D., Chief Executive Officer, Adnexus Therapeutics

John Mendlein has served as our President, Chief Executive Officer and as a member of our board of directors since May 2005. From 2000 to 2005, Dr. Mendlein served as Chairman and Chief Executive Officer at Affinium Pharmaceuticals, Inc., a privately-held biotechnology company focused on developing a new anti-infective class. From 1996 to 2000, Dr. Mendlein served in a variety of roles, including General Counsel and Chief Knowledge Officer, at Aurora Biosciences Corporation, a publicly-traded biotechnology company focused on discovering drugs for kinases, g-protein coupled receptors and ion channels. Previously, Dr. Mendlein worked as an attorney at Cooley Godward Kronish LLP, a law firm, in its life sciences and technology litigation practice groups. Dr. Mendlein also worked at Smith Kline & French Laboratories, Ltd., now GlaxoSmithKline plc, a publicly-traded pharmaceutical company, in the Department of Molecular Biology and Protein Expression. Dr. Mendlein serves as a member of the board of directors of Monogram Biosciences, Inc., a publicly-traded biotechnology company, and the advisory board of Genesys Capital, a venture capital firm. Dr. Mendlein received a J.D. from the University of California Hastings School of Law, a Ph.D. in Physiology and Biophysics from the University of California, Los Angeles and a B.S. in Biology from the University of Miami.

back to top

Noubar Afeyan, Ph.D., Co-Founder of Adnexus Therapeutics and Managing Partner, Flagship Ventures

Noubar B. Afeyan, one of our founders, has served as a member of our board of directors since our inception in 2002. In 1999, Dr. Afeyan founded Flagship Ventures, a venture capital firm, where he serves as Managing Partner and Chief Executive Officer. Dr. Afeyan is also a Senior Lecturer at the Massachusetts Institute of Technology in both the Sloan School of Management and the Biological Engineering Division. Dr. Afeyan serves as a director of Color Kinetics, Inc. and Helicos BioSciences Corporation, both publicly-traded companies, as well as several private companies. Dr. Afeyan received a B.S. in Chemical Engineering from McGill University and a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.

back to top

Amir Nashat, General Partner, Polaris Venture Partners

Amir Nashat has served as a member of our board of directors since June 2007. In 2002, Dr. Nashat joined Polaris Venture Partners, a venture capital firm, where he currently serves as General Partner. Dr. Nashat serves on the board of directors of several private companies. Dr. Nashat received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and his M.S. and B.S. in Materials Science and Mechanical Engineering from the University of California, Berkeley.

back to top

Jean-François Formela, M.D., Senior Partner, Atlas Venture

Jean-François Formela has served as a member of our board of directors since March 2003. Dr. Formela joined Atlas Venture, a venture capital firm, in 1993 and currently serves as Partner. Previously, Dr. Formela was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough Corp., a pharmaceutical company. Dr. Formela serves as a director of Achillion Pharmaceuticals, Inc. and SGX Pharmaceuticals, Inc., both publicly-traded companies, as well as several private companies. Dr. Formela received a M.D. from Paris University School of Medicine and a M.B.A. from Columbia Business School.

back to top

Frank Lee, Ph.D., Co-Founder, Adnexus Therapeutics, and CEO Dragonfly Sciences

Frank D. Lee, one of our founders, has served as a member of our board of directors since our inception in 2002. In 2005, Dr. Lee founded Dragonfly Sciences, Inc., a biology research service company, and is currently its Chief Executive Officer. From 2002 until May 2005, Dr. Lee served as our President and Chief Executive Officer. From 2001 until shortly after our incorporation in 2002, Dr. Lee served as Chief Executive Officer of engeneOS, Inc., a biotechnology company. From 1994 to 2001, Dr. Lee was a member of the senior management team at Millennium Pharmaceuticals, Inc., a biotechnology company, first as Vice President, Research, then as Chief Technology Officer. From 1981 to 1994, Dr. Lee served in various positions at DNAX Research Institute, a division of Schering-Plough, most recently as the Director of Molecular Biology. Dr. Lee received his Ph.D. from Stanford University and carried out postdoctoral research at the Massachusetts Institute of Technology and the Stanford University School of Medicine. He received his B.A. from the University of California, Berkeley.

back to top

Anders Hove, M.D., General Partner, Venrock

Anders D. Hove has served as a member of our board of directors since June 2006. Dr. Hove is a General Partner of Venrock Associates, a venture capital firm, which he joined in 2004. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company and the investment manager of BB Biotech Fund. Dr. Hove is a member of the board of directors of Trubion Pharmaceuticals, Inc., a publicly-traded company, and one private company. He received a M.Sc. from the Technical University of Denmark, a M.D. from the University of Copenhagen and a M.B.A. from INSEAD.

Timothy J. Rink, M.D., Sc.D.

Timothy J. Rink has served as member of our board of directors since August 2007. From 1996 through 1999, Dr. Rink served as Chairman of the Board, President and Chief Executive Officer of Aurora Biosciences Corp., a publicly-traded developer of drug discovery technologies. From 1990 through 1995, Dr. Rink served as the President and Chief Technology Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company, and since then has served as a member of its advisory board. Dr. Rink currently serves on the board of directors of Sepracor, Inc., and Santhera Pharmaceuticals Holding AG, both publicly-traded pharmaceutical companies. Dr. Rink received his M.D. and Sc.D. from the University of Cambridge.

back to top